Appointment

Dechra Pharmaceuticals PLC
25 April 2001


Issued by Citigate Dewe Rogerson, Birmingham

Date: Wednesday, 25 April 2001     Embargoed: 7.00am


                          Dechra Pharmaceuticals PLC

                            Main Board Appointment



Leading manufacturer, distributor and marketer of pharmaceuticals and
veterinary equipment, Dechra Pharmaceuticals PLC announces the further
strengthening of its Main Board with the appointment of Michael Redmond as a
Non-Executive Director with immediate effect.


Mr Redmond, aged 57, has over a number of years gained extensive experience
within the Pharmaceuticals industry.


A graduate of Cambridge University and City University, London, Mr Redmond
previously held senior positions within Glaxo Group plc and Schering Plough
Corporation. In 1991, he joined Fisons plc as Regional Director Europe and in
1993 he was appointed to the Main Board as Managing Director of the
Pharmaceuticals Division. He remained with the Company until March 1996,
playing a key role in the integration of the company into RPR following its
takeover in October 1995.


His other Non-Executive Directorships include Cantab Pharmaceuticals plc and
CeNeS plc.


Commenting on the appointment, Gary Evans, Chief Executive, Dechra
Pharmaceuticals said:-


'We are delighted to welcome Michael to our team. His wealth of experience
within the Pharmaceuticals sector will be invaluable to Dechra.'



Enquiries:

Gary Evans, Chief Executive

Simon Evans, Group Finance Director     Fiona Tooley or Katie Hall

Dechra(R) Pharmaceuticals PLC     Citigate Dewe Rogerson

Telephone: [phone]     Telephone: [phone]

www.dechra.com



There are no details required to be disclosed in relation to paragraph 16.4(b)
of the Listing Rules of the Financial Services Authority.


Notes to Editors:


Dechra are manufacturers, distributors and marketers of pharmaceuticals,
veterinary equipment and related goods and services, predominantly to the UK
veterinary market.


Floated on the London Stock Exchange in September 2000, the Group is
capitalised at £95 million.


The Group's Interim Results announced in February 2001 showed turnover of £
78.54m and pro-forma profit before tax of £3.24m.